The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Multicenter Study Observational StudyIntermediate-term outcomes of aortic valve replacement using a bioprosthesis with a novel tissue.
The COMMENCE trial was conducted to evaluate the safety and effectiveness of an aortic bioprosthesis with novel RESILIA tissue (Edwards Lifesciences, Irvine, Calif). Reports of early noncalcific valve failure resulting from thrombosis or leaflet tears in other valves warrant careful evaluation of early valve performance. ⋯ Safety and hemodynamic performance of this aortic bioprosthesis with RESILIA tissue at 4 years are favorable. This novel tissue does not appear to result in unexpected early thrombosis events or noncalcific structural valve deterioration.
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Aortic progression and reintervention in patients with pathogenic variants after a thoracic aortic dissection.
To evaluate aortic disease progression and reintervention after an initial thoracic aortic dissection in pathogenic variant carriers. ⋯ Aggressive aortic root replacement and similar arch management should be considered in pathogenic variant carriers at initial type A aortic dissection repair compared with benign/normal variant carriers.
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Comparative Study Observational StudyEquivalent 10-year angiographic and long-term clinical outcomes with saphenous vein composite grafts and arterial composite grafts.
We compared 10-year graft patency rates and long-term clinical outcomes after off-pump coronary artery bypass grafting using the saphenous vein composite grafts based on the left internal thoracic artery with those using total arterial composite grafts. ⋯ The saphenous vein composite grafts were equivalent to arterial composite grafts in terms of 10-year graft patency and long-term clinical outcomes.
-
J. Thorac. Cardiovasc. Surg. · Nov 2021
Neonatal heart transplant outcomes: A single institutional experience.
Neonatal orthotopic heart transplantation was introduced in the 1980s as a treatment for complex congenital heart disease. Progress in single-ventricle palliation and biventricular correction has resulted in a decline in neonatal heart transplant volume. However, limited reports on neonatal heart transplants have demonstrated favorable outcomes. We report the long-term outcomes of patients with neonatal heart transplants at our institution spanning nearly 30 years. ⋯ Our institution reports favorable outcomes of neonatal heart transplantation. These results should be considered within the context of outcomes for patients awaiting transplant and the limited donor availability. However, the successful nature of these procedures suggest it may be necessary to reevaluate the indications for neonatal heart transplantation, particularly where risk of mortality and morbidity with palliative or corrective surgery is high.